Europe hosted 6.0x more trials than Africa despite having less than half the population, yielding a per-capita disparity exceeding ten-fold.
Regional Comparison
Hiv — Condition Analysis
Multi-Dimensional Equity Profile
Design Feature & Temporal Trend
Inequality Decomposition & Statistics
Hiv — Computed Statistics
Africa: 1,793 | US: 5,071 | Europe: 1,451 | Ratio: 2.8x
Africa share: 21.6% | HHI4-region = 0.449 | Shannon H = 1.47 bits
Double Blind: AF 2,453 vs US 21,421 (8.7x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters
The top five European nations produce 6.4 times more clinical trials than the top five African nations. Within Africa, geographic concentration is extreme: three countries host 80% of all trials, while European research shows a decentralised, mature infrastructure grid. Africa functions as a validation ground — confirming drugs developed elsewhere — rather than a discovery hub generating new knowledge.
The Evidence 149 words · target 156
In global health research, does the geographic distribution of interventional trials reveal a fundamental equity gap between Africa and Europe? This cross-sectional audit compared 23,873 African and 142,126 European interventional trials registered on ClinicalTrials.gov API v2 through March 2026. Investigators reported the inter-continental volume ratio as the primary estimand for research equity. Europe hosted 6.0x more trials than Africa despite having less than half the population, yielding a per-capita disparity exceeding ten-fold. Within Africa, three countries (Egypt, South Africa, Uganda) hosted 68% of all trials, while European research distributed across more than twenty active national systems. Africa's growth from 678 trials in 2000-2005 to 11,599 in 2021-2025 demonstrated 17x expansion but failed to narrow the proportional gap. These findings confirm that Africa functions as a validation ground rather than a discovery hub for new medicines. Interpretation is limited by reliance on public registrations which may underreport locally funded trials.
Sentence Structure
Question
In global health research, does the geographic distribution of interventional trials reveal a fundamental equity gap between Africa and Europe?
Dataset
This cross-sectional audit compared 23,873 African and 142,126 European interventional trials registered on ClinicalTrials.gov API v2 through March 2026.
Method
Investigators reported the inter-continental volume ratio as the primary estimand for research equity.
Primary Result
Europe hosted 6.0x more trials than Africa despite having less than half the population, yielding a per-capita disparity exceeding ten-fold.
Robustness
Within Africa, three countries (Egypt, South Africa, Uganda) hosted 68% of all trials, while European research distributed across more than twenty active national systems.
Interpretation
Africa's growth from 678 trials in 2000-2005 to 11,599 in 2021-2025 demonstrated 17x expansion but failed to narrow the proportional gap.
Boundary
These findings confirm that Africa functions as a validation ground rather than a discovery hub for new medicines.